Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026)

Regeneron Pharmaceuticals has reported Long-Term Deferred Tax for 16 years, with the latest figure at $4.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 21.73% year-over-year to $4.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (up 21.73% YoY), and the FY2025 full-year result was $4.1 billion, up 23.03% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $4.2 billion, up from $4.1 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $4.2 billion in Q1 2026, with the low at $1.1 billion in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2024.
• Year-over-year, Long-Term Deferred Tax soared 100.79% in 2022 and grew 21.73% in 2026.
• Tracing REGN's Long-Term Deferred Tax over 5 years: stood at $1.7 billion in 2022, then soared by 49.41% to $2.6 billion in 2023, then advanced by 28.68% to $3.3 billion in 2024, then gained by 23.03% to $4.1 billion in 2025, then advanced by 2.79% to $4.2 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $4.2 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.

Peer Comparison